Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | GOT1 | P17174 | 1/20 | 0.44 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.44 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 4/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685608 | 0.80 | TSHR (0.41) | MEN1KMT2AHTR2CANPEPHTR2B | |
| SCHEMBL30843775 | 0.77 | AADAT (0.46) | AADATGOT1KYAT1KYAT3MEN1 | |
| SCHEMBL6652555 | 0.77 | AADAT (0.46) | AADATGOT1KYAT1KYAT3MEN1 | |
| SCHEMBL1673259 | 0.77 | AADAT (0.46) | AADATGOT1KYAT1KYAT3MEN1 | |
| SCHEMBL12094610 | 0.75 | NOTUM (0.44) | AADATGOT1KYAT1KYAT3NOTUM | |
| Bromide SCHEMBL5705627 | 0.75 | AADAT (0.44) | AADATGOT1KYAT1KYAT3MEN1 | |
| Bromide SCHEMBL30825763 | 0.75 | AADAT (0.44) | AADATGOT1KYAT1KYAT3MEN1 | |
| SCHEMBL27416099 | 0.75 | AADAT (0.41) | AADATGOT1KYAT1KYAT3MEN1 | |
| SCHEMBL13070447 | 0.75 | NOTUM (0.53) | AADATMEN1KMT2ANOTUMHTR2A | |
| SCHEMBL3213122 | 0.75 | NOTUM (0.53) | AADATMEN1KMT2ANOTUMHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200321533-A1 | COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE MATERIALS | THE SCRIPPS RESEARCH INSTITUTE | 2020-10-08 | — | — | US | disclosed |
| US-20170244049-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-24 | — | — | US | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1647545-A1 | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| EP-1005493-B1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| EP-1421060-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| WO-2003018537-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| US-6489364-B2 | FROM L-MANNONIC-GAMMA-LACTONE INTERMEDIATES; FOR PROPHYLAXIS OF HIV/AIDS HIV | MEDIVIR AB (SE) | 2002-12-03 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-20010044547-A1 | Antiviral protease inhibitors | MEDIVIR AB | 2001-11-22 | — | — | US | disclosed |
| US-6291687-B1 | USED ASPARTYL PROTEASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | MEDIVIR AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1005493-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998045330-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | AADAT 1096/4885GOT1 38/4885KYAT1 2358/4885 |
| US-20010044547-A1 | Antiviral protease inhibitors | PEPD, PREP, CTSL | AADAT 855/4885GOT1 231/4885KYAT1 1455/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | AADAT 2974/4885GOT1 20/4885KYAT1 3233/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | AADAT 1096/4885GOT1 38/4885KYAT1 2358/4885 |
| US-20200321533-A1 | COMPOUNDS FOR ORGANIC LIGHT EMITTING DIODE MATERIALS | ALDH1A2, DDT, CLTB | AADAT 1238/4885GOT1 3067/4885KYAT1 2296/4885 |
| US-20170244049-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | CYBA, DDT, DRD1 | AADAT 351/4885GOT1 2039/4885KYAT1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.